About This Fund
Atlas Venture Opportunity Fund III is a $400 million follow-on vehicle closed on September 4, 2025 — the largest and third in Atlas's dedicated Opportunity Fund series, which began in 2019 with a $250 million first fund and continued with a $300 million second fund in 2021. Like its predecessors, Opportunity Fund III is reserved exclusively for existing Atlas portfolio companies rather than making new platform investments, giving the firm sustained financial presence through a decade-long journey from founding to commercialization.
The fund is designed to sit alongside Atlas Venture Fund XIV (closed December 2024, $450M), forming Atlas's two-vehicle investment model: Fund XIV seeds and creates early-stage biotechs through its venture creation model; Opportunity Fund III provides the longitudinal 'runway extension' capital as those companies advance through Series B, crossover rounds, IPO processes, and selective follow-on public raises. Partners Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes lead the fund, with Jean-Francois Formela and David Grayzel contributing strategic expertise to portfolio company decisions.
Opportunity Fund III closed oversubscribed against a backdrop of challenging biotech markets. Known limited partners include the New York State Teamsters Conference Pension and Retirement Fund, Penn Mutual Life Insurance Company, and Rutgers University — all described as investors in earlier Atlas vehicles. The fund was structured and closed with legal counsel from Proskauer Rose LLP. The $400M commitment represents a step-up from each prior Opportunity Fund ($250M in 2019, $300M in 2021), reflecting the growing capital needs of an expanding Atlas portfolio.